What is the most suitable antidepressant for an overweight patient concerned about weight gain?

Optimal Antidepressant Selection for Overweight Patients

Bupropion is the definitive first-line antidepressant choice for overweight patients, as it is the only antidepressant consistently associated with weight loss rather than weight gain. 1

Primary Recommendation: Bupropion

• Bupropion promotes weight loss through appetite suppression and reduced food cravings, with 23% of patients losing ≥5 lbs compared to only 11% on placebo in long-term trials. 1, 2
• The FDA has approved bupropion (in combination with naltrexone as Contrave) specifically for chronic weight management, underscoring its weight-loss properties. 1
• In seasonal affective disorder trials lasting up to 6 months, 23% of bupropion-treated patients lost ≥5 lbs versus only 11% on placebo, while weight gain ≥5 lbs occurred in 11% versus 21% on placebo. 2
• A 2024 comparative effectiveness study across 183,118 patients confirmed bupropion showed the least weight gain among all first-line antidepressants, with 0.22 kg less weight gain than sertraline at 6 months and 15% reduced risk of gaining ≥5% baseline weight. 3

Second-Line Options: Weight-Neutral SSRIs

If bupropion is contraindicated (seizure disorders, eating disorders, or concurrent MAOI use), consider these weight-neutral alternatives in order of preference:

• Fluoxetine causes modest weight loss during initial treatment (weeks to months), followed by weight neutrality with long-term use. 1, 4
• Sertraline demonstrates short-term weight loss that transitions to weight neutrality with chronic use. 1
• Both fluoxetine and sertraline rank as the most weight-favorable SSRIs after bupropion. 1

Antidepressants to Absolutely Avoid

• Paroxetine carries the highest risk of weight gain among all SSRIs and should be avoided entirely in overweight patients. 1, 3
• Mirtazapine is closely associated with significant weight gain and ranks among the worst offenders across all antidepressant classes. 1, 5
• Amitriptyline has the greatest weight gain risk among tricyclic antidepressants. 1
• Duloxetine shows higher weight gain than citalopram (0.34 kg more than sertraline at 6 months), making it a poor choice for weight-concerned patients. 1, 3
• Monoamine oxidase inhibitors cause substantial weight gain and should be avoided. 1

Clinical Decision Algorithm

1. First choice: Initiate bupropion unless contraindications exist (seizure history, eating disorders, abrupt alcohol/benzodiazepine discontinuation). 1
2. Second choice: If bupropion is contraindicated or not tolerated, select fluoxetine or sertraline for their weight-neutral profiles. 1
3. Never prescribe: Paroxetine, mirtazapine, amitriptyline, or MAOIs in overweight patients concerned about weight. 1

Important Clinical Caveats

• Not all SSRIs behave identically regarding weight effects—the difference between paroxetine (highest weight gain) and fluoxetine/sertraline (weight-neutral) within the same drug class is clinically significant. 1
• Weight effects vary substantially even within drug classes, making individual agent selection critical rather than class-based prescribing. 5, 3
• The weight-promoting effects of certain antidepressants involve histamine and serotonin off-target appetite-promoting pathways, explaining why some agents cause significant metabolic burden. 5
• Antidepressant-induced weight gain affects 55-65% of patients on high-risk agents and contributes to treatment discontinuation, relapse, and increased risk for type 2 diabetes. 6
• Bupropion's weight-loss mechanism operates through norepinephrine-dopamine reuptake inhibition, fundamentally different from serotonergic agents. 6